Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOPEX open-label extension of Viaskin Peanut in peanut-allergic children
NL-OMON60840Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Mar 2021
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of DBV712 Viaskin® in peanut allergy (2 arms), sponsored by DBV Technologies. Primary endpoints: Proportion reaching eliciting dose of at least 1000 mg peanut protein, Treatment responder rate and 17 more. Started Mar 2021; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NL-OMON60840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60840.